Bessemer Group Inc Gilead Sciences, Inc. Transaction History

Bessemer Group Inc

$60.7 Billion
Q3 2024

A detailed history of Bessemer Group Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 87,594 shares of GILD stock, worth $7.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

87,594

Previous 121,502 27.91%

Holding current value

$7.9 Million

Previous $8.34 Million 11.9%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$66.59 - $83.99 $2.26 Million - $2.85 Million	-33,908 Reduced 27.91%	87,594 $7.34 Million
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $27,154 - $31,338	430 Added 0.36%	121,502 $8.34 Million
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $1.66 Million - $2.03 Million	23,213 Added 23.72%	121,072 $8.87 Million
Q4 2023 Feb 09, 2024	BUY	$73.27 - $83.09 $439,033 - $497,875	5,992 Added 6.52%	97,859 $7.93 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $1.95 Million - $2.13 Million	26,381 Added 40.28%	91,867 $6.89 Million
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $340,676 - $388,589	4,482 Added 7.35%	65,486 $5.05 Million
Q1 2023 May 10, 2023	SELL	$77.31 - $88.08 $24,739 - $28,185	-320 Reduced 0.52%	61,004 $5.06 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $91,672 - $131,610	-1,471 Reduced 2.34%	61,324 $5.27 Million
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $572,119 - $653,508	9,609 Added 18.07%	62,795 $3.87 Million
Q2 2022 Aug 10, 2022	SELL	$57.72 - $65.01 $254,198 - $286,304	-4,404 Reduced 7.65%	53,186 $3.29 Million
Q1 2022 May 12, 2022	BUY	$57.92 - $72.58 $657,739 - $824,218	11,356 Added 24.56%	57,590 $3.42 Million
Q4 2021 Jan 27, 2022	SELL	$64.88 - $73.64 $504,312 - $572,403	-7,773 Reduced 14.39%	46,234 $3.36 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $96,322 - $103,921	1,423 Added 2.71%	54,007 $3.77 Million
Q2 2021 Aug 06, 2021	BUY	$63.47 - $69.35 $129,859 - $141,890	2,046 Added 4.05%	52,584 $3.62 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $235,920 - $269,184	3,932 Added 8.44%	50,538 $3.27 Million
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $122,873 - $140,008	-2,169 Reduced 4.45%	46,606 $2.72 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $1.54 Million - $1.94 Million	-24,841 Reduced 33.74%	48,775 $3.08 Million
Q2 2020 Aug 05, 2020	BUY	$72.34 - $84.0 $2.15 Million - $2.5 Million	29,752 Added 67.83%	73,616 $5.66 Million
Q1 2020 Apr 30, 2020	BUY	$62.63 - $80.22 $76,283 - $97,707	1,218 Added 2.86%	43,864 $3.28 Million
Q4 2019 Feb 04, 2020	SELL	$61.62 - $67.78 $43,750 - $48,123	-710 Reduced 1.64%	42,646 $2.77 Million
Q3 2019 Nov 07, 2019	BUY	$62.51 - $69.0 $588,344 - $649,428	9,412 Added 27.73%	43,356 $2.75 Million
Q2 2019 Jul 19, 2019	BUY	$61.87 - $69.38 $38,359 - $43,015	620 Added 1.86%	33,944 $2.29 Million
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $236,363 - $264,789	-3,780 Reduced 10.19%	33,324 $2.17 Million
Q4 2018 Feb 12, 2019	BUY	$60.54 - $79.0 $392,722 - $512,473	6,487 Added 21.19%	37,104 $2.32 Million
Q3 2018 Nov 06, 2018	SELL	$71.28 - $78.92 $68,927 - $76,315	-967 Reduced 3.06%	30,617 $2.36 Million
Q2 2018 Jul 25, 2018	SELL	$64.88 - $75.68 $263,218 - $307,033	-4,057 Reduced 11.38%	31,584 $2.24 Million
Q1 2018 May 10, 2018	SELL	$72.84 - $88.8 $319,913 - $390,009	-4,392 Reduced 10.97%	35,641 $2.69 Million
Q4 2017 Jan 30, 2018	SELL	$71.15 - $83.52 $92.5 Million - $109 Million	-1,299,509 Reduced 97.01%	40,033 $2.87 Million
Q3 2017 Nov 03, 2017	BUY	$72.11 - $85.47 $96.6 Million - $114 Million	1,339,542	1,339,542 $109 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.

Account

Bessemer Group Inc Gilead Sciences, Inc. Transaction History